Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability
Nanomaterials · 18.02.2026 · 16 (4) · 268
DOI: 10.3390/nano16040268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nanomaterials, online erschienen am 18.02.2026. Verfasst von Alireza Nomani und 15 weiteren Autor:innen. Beteiligte Einrichtung: Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The long-term stability of mRNA-lipid nanoparticles (LNPs), essential for mRNA vaccines and gene therapies, relies on managing physicochemical properties to preserve their integrity and effectiveness through optimized formulation components. This study systematically evaluated LNP formulations with varied compositions, e.g., Dlin-MC3-DMA and ALC-0315 as ionizable lipids, and DMG-PEG2k or ALC-0159 as polyethylene glycol (PEG)-lipids, stored at −80 °C, −20 °C, 5 °C, and 25 °C in Tris buffer (pH 7.4) for 12 months.
Methods
Sixteen quality attributes were analyzed, including particle size, mRNA encapsulation, lipid oxidation, and transfection efficiency over different formulations and storage temperatures to mechanistically evaluate the long-term stabilities.
Results
Formulations stored at −80 °C and −20 °C retained acceptable stability, while storage at 5 °C caused aggregation, reduced in vivo expression, and mRNA degradation. Storage at 25 °C led to complete loss of transfection within six months. Mechanistic studies identified oxidative and hydrolytic lipid degradation (e.g., DSPC) in ALC-0315 formulations and MC3 N-oxidation with subvisible particulates in MC3-containing LNPs as primary failure modes. Increasing Tris buffer concentration accelerated 5′-cap hydrolysis, emphasizing the importance of a low-ionic-strength buffer for LNP formulations.
Conclusions
Findings re-emphasize the necessity of deep-cold storage (≤−20 °C) and optimized formulation components to preserve mRNA–LNP integrity, offering insights for designing next-generation LNPs with improved shelf-life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Product Development & Technology, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
- Regeneron Genetic Medicines, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
- Analytical & Biological Mass Spectrometry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
- Product Biochemistry, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA.
ORCID-Profile: Alireza Nomani, Jikang Wu, Haibo Qiu
Zitieren
APA
Nomani, A., Saraswat, A., Brown, H., Kuo, J. C., Duong, H. T. T., Wu, J., Zhang, Y., Fu, Y., Moon, Y., Wahidi, S., Mejia, N., Hartford, S., Qiu, H., Rayaprolu, B., Bhalla, A. S., & Shameem, M. (2026). Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability. Nanomaterials, 16(4), 268. https://doi.org/10.3390/nano16040268
Vancouver
Nomani A, Saraswat A, Brown H, Kuo JC, Duong HTT, Wu J, et al. Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability. Nanomaterials. 2026;16(4):268. doi:10.3390/nano16040268
BibTeX
@article{Nomani2026,
author = {Nomani, Alireza and Saraswat, Aishwarya and Brown, Heather and Kuo, Jimmy Chun-Tien and Duong, Huu Thuy Trang and Wu, Jikang and Zhang, Yu and Fu, Yue and Moon, Youmi and Wahidi, Shafiq and Mejia, Nancy and Hartford, Suzanne and Qiu, Haibo and Rayaprolu, Bindhu and Bhalla, Amardeep S and Shameem, Mohammed},
title = {Identifying Key Factors Affecting mRNA-Lipid Nanoparticles Drug Product Formulation Stability},
journal = {Nanomaterials},
year = {2026},
volume = {16},
number = {4},
pages = {268},
doi = {10.3390/nano16040268}
}
EUVIMED